**Table 2:** Clinical data in study group.

|  |  |
| --- | --- |
| **Item** | **Descriptive** |
| 1- |  |
| IDC | 92 (89.3%) |
| Medullary | 4 (3.9%) |
| ILC | 7 (6.8%) |
| **2-Grade:** |  |
| I | 2 (1.9%) |
| II | 95 (92.2%) |
| III | 6 (5.8%) |
| **1-       Type of surgery:** |  |
| MRM | 82 (79.6%) |
| BCS | 21 (20.4%) |
|  |  |
| **4-T:** |  |
| X | 6 (5.8%) |
| 1 | 6 (5.8%) |
| 2 | 63 (61.2%) |
| 3 | 22 (21.4%) |
| 4 | 6 (5.8%) |
| 5**-LN number:** |  |
| 0 | 14 (13.6%) |
| 1 | 17 (16.5%) |
| 2 | 24 (23.3%) |
| 3 | 18 (17.5%) |
| 4 | 10 (9.7%) |
| 5 | 14 (13.6%) |
| 6 | 6 (5.8%) |
| **6-Extracapsular invasion:** |  |
| no | 45 (43.7%) |
| yes | 34 (33.0%) |
| unknown | 24 (23.3%) |
| **7-ER:** |  |
| Positive | 64 (62.1%) |
| Negative | 38 (36.9%) |
| Unknown | 1 (1.0%) |
|  |  |
| **8-PR:** |  |
| Positive | 53 (51.5%) |
| Negative | 48 (46.6%) |
| Unknown | 2 (1.9%) |
| **9- Her2-neu** |  |
| Positive | 6 (5.8%) |
| Negative | 37 (35.9%) |
| Unknown | 60 (58.3%) |
| **10-Chemotherapy:** |  |
| CMF | 7 (6.8%) |
| FAC | 61 (59.2%) |
| FEC | 28 (27.2%) |
| taxane based | 3 (2.9%) |
| Herceptin | 1 (1.0%) |
| No CTR | 3 (2.9%) |
| **11- Radiotherapy:** |  |
| CW + PL | 90 (87.4%) |
| CW | 7 (6.8%) |
| no Rth | 6 (5.8%) |
| **12-Hormonal treatment:** |  |
| Tam | 55 (53.4%) |
| AIs | 12 (11.7%) |
| Not given | 34 (33.0%) |
| Tam and Zoladex | 2 (1.9%) |
| **13-Type of progression:** |  |
| Local | 3 (2.9%) |
| local and distant | 5 (4.9%) |
| distant | 31 (30.1%) |
| No progression | 64 (62.1%) |